Why Societe Generale (SCGLY) Could Be a Top Value Stock Pick

Value investing is always a very popular strategy, and for good reason. After all, who doesn’t want to find stocks that have low PEs, solid outlooks, and decent dividends?

Fortunately for investors looking for this combination, we have identified a strong candidate which may be an impressive value; Societe Generale Societe anonyme SCGLY.

Societe Generale in Focus

SCGLY may be an interesting play thanks to its forward PE of 8.2, its P/S ratio of 0.9, and its decent dividend yield of 1.6%. These factors suggest that Societe Generale is a pretty good value pick, as investors have to pay a relatively low level for each dollar of earnings, and that SCGLY has decent revenue metrics to back up its earnings.

Societe Generale Societe anonyme PE Ratio (TTM)

Societe Generale Group PE Ratio (TTM)

Societe Generale Societe anonyme pe-ratio-ttm | Societe Generale Societe anonyme Quote

But before you think that Societe Generale is just a pure value play, it is important to note that it has been seeing solid activity on the earnings estimate front as well. For current year earnings, the consensus has gone up by 24.6% in the past 60 days, thanks to two upward revisions in the past two months compared to none lower.

This estimate strength is actually enough to push SCGLY to a Zacks Rank #2 (Buy), suggesting it is poised to outperform. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

So really, Societe Generale is looking great from a number of angles thanks to its PE below 20, a P/S ratio below one, and a strong Zacks Rank, meaning that this company could be a great choice for value investors at this time.

Breakout Biotech Stocks with Triple-Digit Profit Potential

The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.

Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.

See these 7 breakthrough stocks now>>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Societe Generale Group (SCGLY) : Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research